Shares of AstraZeneca Pharma India gained as much as 3 percent to Rs 6,890 in afternoon trade on March 3 after the company announced it has secured regulatory approval to expand the use of its cancer therapy, Imfinzi, in the country.
The Central Drugs Standard Control Organisation (CDSCO) has granted the company permission to import, sell, and distribute Durvalumab (Imfinzi) for an additional indication—treating patients with unresectable hepatocellular carcinoma (uHCC), a form of liver cancer.
Follow our LIVE blog for all the latest market updates
This approval allows the use of Durvalumab in combination with Tremelimumab, broadening treatment options for patients battling advanced-stage liver cancer. While the company still requires other statutory approvals before launching the expanded indication in India, the regulatory green light marks a crucial step in AstraZeneca Pharma’s oncology portfolio expansion.
AstraZeneca Pharma India delivered a stellar performance in Q3FY25, with net profit surging 94.9 percent year-on-year to Rs 30.8 crore, up from Rs 15.8 crore in the same period last year.
Also read: FIR order against Madhabi Puri Buch, 5 others: Bombay HC to hear SEBI, BSE appeals on March 4
The company’s revenue jumped 44 percent YoY to Rs 440.3 crore, driven by strong demand for its pharmaceutical products. Operationally, EBITDA soared to Rs 76.9 crore from Rs 15.1 crore in Q3FY24, buoyed by higher sales and improved cost efficiencies.
Profitability saw a sharp uptick, with the EBITDA margin expanding to 17.5 percent from 4.9 percent a year ago. The strong earnings performance underscores the company’s growth momentum as it continues to strengthen its presence in India’s pharmaceutical market.
Read more: Founder stakes in unicorn startups decline amid a challenging funding environment
At about 2:45 pm, shares of the company were trading at Rs 6,852, higher by 2.3 percent from the last close on the NSE. AstraZeneca Pharma shares have crashed 8 percent in the last month and about 6 percent since the start of the year.
Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
